Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Omeros Corp. (NASDAQ: OMER).

Full DD Report for OMER

You must become a subscriber to view this report.


Recent News from (NASDAQ: OMER)

Omeros Announces Additions to Senior Management Team
-- Hires Commercial and CMC Heads from Celgene -- Omeros Corporation (Nasdaq: OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.D. as vice president of chemistry, manufacturi...
Source: Business Wire
Date: December, 03 2018 08:30
New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omeros Corporation (NASDAQ:OMER), Apple Inc. (NASDAQ:AAPL), Bio-Rad La...
Source: GlobeNewswire
Date: November, 30 2018 08:25
Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens. Omeros management will host a conference call and webcast that day at 8:30 a.m...
Source: Business Wire
Date: November, 05 2018 07:00
Omeros' OMS721 an Orphan Drug in U.S. for HSCT-associated clotting disorder; shares ahead 9%
The FDA grants Orphan Drug status for Omeros' ( OMER +8.9% ) lead candidate OMS721 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a severe complication of HSCT characterized by blood clotting in the smallest blood vessels in the ...
Source: SeekingAlpha
Date: October, 23 2018 12:45
FDA Grants Orphan Drug Designation to Omeros' OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
-- OMS721 now with orphan designation covering both prevention and treatment of HSCT-TMA in U.S. and in Europe -- Omeros Corporation (NASDAQ:OMER) today announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment ...
Source: Business Wire
Date: October, 23 2018 08:30
New Research: Key Drivers of Growth for Hecla Mining, Atlas Air Worldwide, Encana, Omeros, Lowe's Companies, and Oaktree Specialty Lending - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hecla Mining Company (NYSE:HL), Atlas Air Worldwide Holdings (NASDAQ:AAWW...
Source: GlobeNewswire
Date: October, 23 2018 07:30
Your Daily Pharma Scoop: Omeros Positive, Five Prime's Milestone
Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space and also provide quick commentary on other imp...
Source: SeekingAlpha
Date: October, 03 2018 13:29
Premarket Gainers as of 9:05 am (10/02/2018)
DTEA +39%  on speculative move . More news on: DAVIDs TEA, Cellectar Biosciences, Inc., Oragenics, Inc., Stocks on the move, , Top stock market news, Read more ...
Source: SeekingAlpha
Date: October, 02 2018 09:23
Today's Research Reports on Trending Tickers: Omeros and Sarepta Therapeutics
NEW YORK, NY / ACCESSWIRE / October 2, 2018 / U.S. equities were mixed on Monday after the U.S. and Canada agreed to revise the current North American Free Trade Agreement. The Dow Jones Industrial Average gained 0.73 percent to close at 26,651.21, while the S&P 500 Index closed 0.36 pe...
Source: ACCESSWIRE IA
Date: October, 02 2018 08:00
After Hours Gainers / Losers (10/01/2018)
Top Gainers:   IGC   +11.4% . OMER +9.9% . DTEA +9.4% . SENS +4.6% . SYN   +3.9% . More news on: India Globalization Capital, Inc, Omeros Corporation, DAVIDs TEA, Stocks on the move, , News on ETFs, Top stock market news, Read more ...
Source: SeekingAlpha
Date: October, 01 2018 17:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1014.0213.8514.1813.22498,581
2018-12-0714.2614.0214.677513.805615,593
2018-12-0613.5214.2814.3213.25720,911
2018-12-0414.0013.6214.6013.555967,925
2018-12-0314.2014.0414.5913.42828,621

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1046,51981,71556.9283Short
2018-12-0766,718118,46556.3187Short
2018-12-0698,221176,04355.7938Short
2018-12-04387,472439,70888.1203Short
2018-12-0394,570186,15950.8007Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OMER.


About Omeros Corp. (NASDAQ: OMER)

Logo for Omeros Corp. (NASDAQ: OMER)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $960,408,102 - 05/11/2018
  • Issue and Outstanding: 48,285,978 - 02/26/2018

 


Recent Filings from (NASDAQ: OMER)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 01 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 09 2018

 

 


Daily Technical Chart for (NASDAQ: OMER)

Daily Technical Chart for (NASDAQ: OMER)


Stay tuned for daily updates and more on (NASDAQ: OMER)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: OMER)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OMER is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of OMER and does not buy, sell, or trade any shares of OMER. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/